218 related articles for article (PubMed ID: 15006494)
1. Neurotensin, schizophrenia, and antipsychotic drug action.
Kinkead B; Nemeroff CB
Int Rev Neurobiol; 2004; 59():327-49. PubMed ID: 15006494
[TBL] [Abstract][Full Text] [Related]
2. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?
Cáceda R; Kinkead B; Nemeroff CB
Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409
[TBL] [Abstract][Full Text] [Related]
3. Neurotensin: role in psychiatric and neurological diseases.
Cáceda R; Kinkead B; Nemeroff CB
Peptides; 2006 Oct; 27(10):2385-404. PubMed ID: 16891042
[TBL] [Abstract][Full Text] [Related]
4. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs.
Stowe ZN; Bissette G; Nemeroff CB
Yakubutsu Seishin Kodo; 1991 Feb; 11(1):49-59. PubMed ID: 1679273
[TBL] [Abstract][Full Text] [Related]
5. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs.
Binder EB; Kinkead B; Owens MJ; Nemeroff CB
Biol Psychiatry; 2001 Dec; 50(11):856-72. PubMed ID: 11743941
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice.
Mechanic JA; Sutton JE; Berson AE; Wu X; Kwan J; Schreiber R; Pang Z; Button DC
Eur Neuropsychopharmacol; 2009 Jul; 19(7):466-75. PubMed ID: 19223157
[TBL] [Abstract][Full Text] [Related]
7. Novel treatments of schizophrenia: targeting the neurotensin system.
Kinkead B; Nemeroff CB
CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):205-18. PubMed ID: 16611093
[TBL] [Abstract][Full Text] [Related]
8. The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system.
Kinkead B; Nemeroff CB
J Clin Psychiatry; 1994 Sep; 55 Suppl B():30-2. PubMed ID: 7961568
[TBL] [Abstract][Full Text] [Related]
9. Bioactive analogs of neurotensin: focus on CNS effects.
Boules M; Fredrickson P; Richelson E
Peptides; 2006 Oct; 27(10):2523-33. PubMed ID: 16882457
[TBL] [Abstract][Full Text] [Related]
10. Neurotensin and dopamine interactions.
Binder EB; Kinkead B; Owens MJ; Nemeroff CB
Pharmacol Rev; 2001 Dec; 53(4):453-86. PubMed ID: 11734615
[TBL] [Abstract][Full Text] [Related]
11. Brain neurotensin, psychostimulants, and stress--emphasis on neuroanatomical substrates.
Geisler S; Bérod A; Zahm DS; Rostène W
Peptides; 2006 Oct; 27(10):2364-84. PubMed ID: 16934369
[TBL] [Abstract][Full Text] [Related]
12. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.
Binder EB; Kinkead B; Owens MJ; Kilts CD; Nemeroff CB
J Neurosci; 2001 Jan; 21(2):601-8. PubMed ID: 11160439
[TBL] [Abstract][Full Text] [Related]
13. Does neurotensin mediate the effects of antipsychotic drugs?
Kinkead B; Binder EB; Nemeroff CB
Biol Psychiatry; 1999 Aug; 46(3):340-51. PubMed ID: 10435199
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues.
Hadden MK; Orwig KS; Kokko KP; Mazella J; Dix TA
Neuropharmacology; 2005 Dec; 49(8):1149-59. PubMed ID: 16095636
[TBL] [Abstract][Full Text] [Related]
15. Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs.
Gruber SH; Nomikos GG; Mathé AA
Eur Neuropsychopharmacol; 2006 Dec; 16(8):592-600. PubMed ID: 16524702
[TBL] [Abstract][Full Text] [Related]
16. Neurotensin agonists: potential in the treatment of schizophrenia.
Boules M; Shaw A; Fredrickson P; Richelson E
CNS Drugs; 2007; 21(1):13-23. PubMed ID: 17190526
[TBL] [Abstract][Full Text] [Related]
17. [Neurotensin--structure, origin and biological function].
Kulińska-Niedziela I; Paluszak J
Postepy Hig Med Dosw; 1997; 51(3):329-42. PubMed ID: 9333784
[TBL] [Abstract][Full Text] [Related]
18. Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion.
Norman C; Beckett SR; Spicer CH; Ashton D; Langlois X; Bennett GW
J Psychopharmacol; 2008 May; 22(3):300-7. PubMed ID: 18208905
[TBL] [Abstract][Full Text] [Related]
19. [New pharmacological approaches to the treatment of schizophrenia].
Uzbay IT
Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
[TBL] [Abstract][Full Text] [Related]
20. Do neuropeptide systems mediate some of the effects of antipsychotic drugs?
Bissette G; Nemeroff CB
Prog Clin Biol Res; 1985; 192():349-53. PubMed ID: 2867552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
